Associations between pathogenic variant and brain atrophy rates in familial frontotemporal dementia

Takeaway

  • Rates of atrophy increased with disease progression in people with MAPT and GRN variants, whereas C9orf72 carriers demonstrated minimal increase in rate of volume loss with disease stage.

Why this matters ?

  • Mechanisms of symptomatic disease may vary between pathogenic variants.

  • Better understanding of brain atrophy dynamics in frontotemporal lobar degeneration
    (f-FTLD) may improve the power to detect a treatment effect in future clinical trials.

International Medical Press is a global provider of independent medical education. Its mission is to provide healthcare professionals with high-quality, trusted medical information with the aim of helping optimize patient care.

No responsibility is assumed by International Medical Press for any injury and/or damage to persons or property through negligence or otherwise, or from any use or operation of any methods, products, instructions, or ideas contained in the material herein. Because of rapid advances in the medical sciences, International Medical Press recommends that independent verification of diagnoses and drug dosages should be made. The opinions expressed do not reflect those of International Medical Press or the sponsor. International Medical Press assumes no liability for any material contained herein.